Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadso...
Gespeichert in:
| Veröffentlicht in: | Acta dermato-venereologica 2016-01, Vol.96 (1), p.72-76 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 76 |
|---|---|
| container_issue | 1 |
| container_start_page | 72 |
| container_title | Acta dermato-venereologica |
| container_volume | 96 |
| creator | Zink, Alexander Gensbaur, Anna Zirbs, Michael Seifert, Florian Suarez, Isabel Leon Mourantchanian, Vagkan Weidinger, Stephan Mempel, Martin Ring, Johannes Ollert, Markus |
| description | Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels. |
| doi_str_mv | 10.2340/00015555-2165 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760931730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760931730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-b31f6fde2647f7b9d21ae75f63a46477af82c226cbe178d80395617377a1484a3</originalsourceid><addsrcrecordid>eNo9kL1PwzAQxS0EoqUwsiKPLAF_JHYyVqVApUodKLPlJHYxiuNgJyD463Foyw13uvd-d8MD4BqjO0JTdI8QwlmshGCWnYBp7DghKOOnYDp6yWhOwEUI73ElGc7PwYQwlBUpSadAbKXfqd60O7jaLaFp4Yv6VF7Bee86U8EH5a3sTW8C_DL9G5Rw4Wxp2qi5FjoNV9YOrZN1cL7702Rbw42VjfkZrCwvwZmWTVBXhzkDr4_L7eI5WW-eVov5OqkoJX1SUqyZrhVhKde8LGqCpeKZZlSmUeJS56QihFWlwjyvc0SLjGFOo4PTPJV0Bm73fzvvPgYVemFNqFTTyFa5IQjMGSpovEARTfZo5V0IXmnReWOl_xYYiTFTccxUjJlG_ubweiitqv_pY4j0F745cGc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760931730</pqid></control><display><type>article</type><title>Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Zink, Alexander ; Gensbaur, Anna ; Zirbs, Michael ; Seifert, Florian ; Suarez, Isabel Leon ; Mourantchanian, Vagkan ; Weidinger, Stephan ; Mempel, Martin ; Ring, Johannes ; Ollert, Markus</creator><creatorcontrib>Zink, Alexander ; Gensbaur, Anna ; Zirbs, Michael ; Seifert, Florian ; Suarez, Isabel Leon ; Mourantchanian, Vagkan ; Weidinger, Stephan ; Mempel, Martin ; Ring, Johannes ; Ollert, Markus</creatorcontrib><description>Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.</description><identifier>ISSN: 0001-5555</identifier><identifier>EISSN: 1651-2057</identifier><identifier>DOI: 10.2340/00015555-2165</identifier><identifier>PMID: 26059424</identifier><language>eng</language><publisher>Sweden</publisher><subject>Adult ; Aged ; Anti-Allergic Agents - adverse effects ; Anti-Allergic Agents - therapeutic use ; Biomarkers - blood ; Blood Component Removal - adverse effects ; Combined Modality Therapy ; Dermatitis, Atopic - blood ; Dermatitis, Atopic - diagnosis ; Dermatitis, Atopic - immunology ; Dermatitis, Atopic - therapy ; Disease Progression ; Female ; Humans ; Immunoglobulin E - blood ; Immunosorbent Techniques - adverse effects ; Male ; Middle Aged ; Omalizumab - adverse effects ; Omalizumab - therapeutic use ; Pilot Projects ; Remission Induction ; Severity of Illness Index ; Time Factors ; Treatment Outcome</subject><ispartof>Acta dermato-venereologica, 2016-01, Vol.96 (1), p.72-76</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-b31f6fde2647f7b9d21ae75f63a46477af82c226cbe178d80395617377a1484a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26059424$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zink, Alexander</creatorcontrib><creatorcontrib>Gensbaur, Anna</creatorcontrib><creatorcontrib>Zirbs, Michael</creatorcontrib><creatorcontrib>Seifert, Florian</creatorcontrib><creatorcontrib>Suarez, Isabel Leon</creatorcontrib><creatorcontrib>Mourantchanian, Vagkan</creatorcontrib><creatorcontrib>Weidinger, Stephan</creatorcontrib><creatorcontrib>Mempel, Martin</creatorcontrib><creatorcontrib>Ring, Johannes</creatorcontrib><creatorcontrib>Ollert, Markus</creatorcontrib><title>Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Allergic Agents - adverse effects</subject><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Blood Component Removal - adverse effects</subject><subject>Combined Modality Therapy</subject><subject>Dermatitis, Atopic - blood</subject><subject>Dermatitis, Atopic - diagnosis</subject><subject>Dermatitis, Atopic - immunology</subject><subject>Dermatitis, Atopic - therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Immunosorbent Techniques - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Omalizumab - adverse effects</subject><subject>Omalizumab - therapeutic use</subject><subject>Pilot Projects</subject><subject>Remission Induction</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0001-5555</issn><issn>1651-2057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kL1PwzAQxS0EoqUwsiKPLAF_JHYyVqVApUodKLPlJHYxiuNgJyD463Foyw13uvd-d8MD4BqjO0JTdI8QwlmshGCWnYBp7DghKOOnYDp6yWhOwEUI73ElGc7PwYQwlBUpSadAbKXfqd60O7jaLaFp4Yv6VF7Bee86U8EH5a3sTW8C_DL9G5Rw4Wxp2qi5FjoNV9YOrZN1cL7702Rbw42VjfkZrCwvwZmWTVBXhzkDr4_L7eI5WW-eVov5OqkoJX1SUqyZrhVhKde8LGqCpeKZZlSmUeJS56QihFWlwjyvc0SLjGFOo4PTPJV0Bm73fzvvPgYVemFNqFTTyFa5IQjMGSpovEARTfZo5V0IXmnReWOl_xYYiTFTccxUjJlG_ubweiitqv_pY4j0F745cGc</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Zink, Alexander</creator><creator>Gensbaur, Anna</creator><creator>Zirbs, Michael</creator><creator>Seifert, Florian</creator><creator>Suarez, Isabel Leon</creator><creator>Mourantchanian, Vagkan</creator><creator>Weidinger, Stephan</creator><creator>Mempel, Martin</creator><creator>Ring, Johannes</creator><creator>Ollert, Markus</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201601</creationdate><title>Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab</title><author>Zink, Alexander ; Gensbaur, Anna ; Zirbs, Michael ; Seifert, Florian ; Suarez, Isabel Leon ; Mourantchanian, Vagkan ; Weidinger, Stephan ; Mempel, Martin ; Ring, Johannes ; Ollert, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-b31f6fde2647f7b9d21ae75f63a46477af82c226cbe178d80395617377a1484a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Allergic Agents - adverse effects</topic><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Blood Component Removal - adverse effects</topic><topic>Combined Modality Therapy</topic><topic>Dermatitis, Atopic - blood</topic><topic>Dermatitis, Atopic - diagnosis</topic><topic>Dermatitis, Atopic - immunology</topic><topic>Dermatitis, Atopic - therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Immunosorbent Techniques - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Omalizumab - adverse effects</topic><topic>Omalizumab - therapeutic use</topic><topic>Pilot Projects</topic><topic>Remission Induction</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zink, Alexander</creatorcontrib><creatorcontrib>Gensbaur, Anna</creatorcontrib><creatorcontrib>Zirbs, Michael</creatorcontrib><creatorcontrib>Seifert, Florian</creatorcontrib><creatorcontrib>Suarez, Isabel Leon</creatorcontrib><creatorcontrib>Mourantchanian, Vagkan</creatorcontrib><creatorcontrib>Weidinger, Stephan</creatorcontrib><creatorcontrib>Mempel, Martin</creatorcontrib><creatorcontrib>Ring, Johannes</creatorcontrib><creatorcontrib>Ollert, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zink, Alexander</au><au>Gensbaur, Anna</au><au>Zirbs, Michael</au><au>Seifert, Florian</au><au>Suarez, Isabel Leon</au><au>Mourantchanian, Vagkan</au><au>Weidinger, Stephan</au><au>Mempel, Martin</au><au>Ring, Johannes</au><au>Ollert, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>2016-01</date><risdate>2016</risdate><volume>96</volume><issue>1</issue><spage>72</spage><epage>76</epage><pages>72-76</pages><issn>0001-5555</issn><eissn>1651-2057</eissn><abstract>Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.</abstract><cop>Sweden</cop><pmid>26059424</pmid><doi>10.2340/00015555-2165</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5555 |
| ispartof | Acta dermato-venereologica, 2016-01, Vol.96 (1), p.72-76 |
| issn | 0001-5555 1651-2057 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760931730 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Anti-Allergic Agents - adverse effects Anti-Allergic Agents - therapeutic use Biomarkers - blood Blood Component Removal - adverse effects Combined Modality Therapy Dermatitis, Atopic - blood Dermatitis, Atopic - diagnosis Dermatitis, Atopic - immunology Dermatitis, Atopic - therapy Disease Progression Female Humans Immunoglobulin E - blood Immunosorbent Techniques - adverse effects Male Middle Aged Omalizumab - adverse effects Omalizumab - therapeutic use Pilot Projects Remission Induction Severity of Illness Index Time Factors Treatment Outcome |
| title | Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A23%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20IgE%20in%20Severe%20Atopic%20Dermatitis%20with%20a%20Combination%20of%20Immunoadsorption%20and%20Omalizumab&rft.jtitle=Acta%20dermato-venereologica&rft.au=Zink,%20Alexander&rft.date=2016-01&rft.volume=96&rft.issue=1&rft.spage=72&rft.epage=76&rft.pages=72-76&rft.issn=0001-5555&rft.eissn=1651-2057&rft_id=info:doi/10.2340/00015555-2165&rft_dat=%3Cproquest_cross%3E1760931730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760931730&rft_id=info:pmid/26059424&rfr_iscdi=true |